{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T08:28:41Z","timestamp":1793953721334,"version":"4.8.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003803","name":"University of Hong Kong","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003803","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["RTF24jul-0007"],"award-info":[{"award-number":["RTF24jul-0007"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001350","name":"Ministry of Health -Singapore","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001350","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["akdh.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Kidney Disease and Health"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1053\/j.akdh.2025.12.003","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T02:33:34Z","timestamp":1782182014000},"page":"15-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Autosomal Dominant Polycystic Kidney Disease: Genetic Insights, Phenotypic Spectrum, and Advances in Prognosis and Treatment"],"prefix":"10.1053","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-8202-8072","authenticated-orcid":false,"given":"Ru Sin","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9267-7956","authenticated-orcid":false,"given":"Becky Mingyao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0809-5054","authenticated-orcid":false,"given":"Kitty","family":"St Pierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Biros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8752-2551","authenticated-orcid":false,"given":"Andrew J.","family":"Mallett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1053\/j.akdh.2025.12.003_bib1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1053\/j.ajkd.2017.08.020","article-title":"Development of the autosomal dominant polycystic kidney disease impact scale: a new health-related quality-of-life instrument","volume":"71","author":"Oberdhan","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"15","key":"10.1053\/j.akdh.2025.12.003_bib2","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.akdh.2025.12.003_bib3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1053\/j.akdh.2025.12.003_bib4","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1053\/j.akdh.2025.12.003_bib5","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.ajhg.2016.05.004","article-title":"Mutations in GANAB, encoding the glucosidase II\u03b1 subunit, cause autosomal-dominant polycystic kidney and liver disease","volume":"98","author":"Porath","year":"2016","journal-title":"Am J Hum Genet"},{"issue":"10","key":"10.1053\/j.akdh.2025.12.003_bib6","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1681\/ASN.2018050493","article-title":"Prevalence estimates of polycystic kidney and liver disease by population sequencing","volume":"29","author":"Lanktree","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.akdh.2025.12.003_bib7","series-title":"StatPearls","article-title":"Autosomal recessive polycystic kidney disease","author":"Subramanian","year":"2025"},{"issue":"2","key":"10.1053\/j.akdh.2025.12.003_bib8","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2024.07.009","article-title":"KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD)","volume":"107","author":"Devuyst","year":"2025","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.akdh.2025.12.003_bib9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1681\/ASN.2017050483","article-title":"Genetic complexity of autosomal dominant polycystic kidney and liver diseases","volume":"29","author":"Cornec-Le Gall","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.akdh.2025.12.003_bib10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/ng0695-151","article-title":"The polycystic kidney disease 1 (PKD1) gene encodes a novel protein with multiple cell recognition domains","volume":"10","author":"Hughes","year":"1995","journal-title":"Nat Genet"},{"issue":"2","key":"10.1053\/j.akdh.2025.12.003_bib11","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0092-8674(95)90339-9","article-title":"Polycystic kidney disease: the complete structure of the pkd1 gene and its protein the International Polycystic Kidney Disease Consortium","volume":"81","year":"1995","journal-title":"Cell"},{"issue":"6","key":"10.1053\/j.akdh.2025.12.003_bib12","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1053\/j.ajkd.2008.05.015","article-title":"Presence of de novo mutations in autosomal dominant polycystic kidney disease patients without family history","volume":"52","author":"Reed","year":"2008","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"10.1053\/j.akdh.2025.12.003_bib13","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1681\/ASN.2016090938","article-title":"Polycystic kidney disease without an apparent family history","volume":"28","author":"Iliuta","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.akdh.2025.12.003_bib14","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.kint.2019.11.019","article-title":"Next-generation sequencing for detection of somatic mosaicism in autosomal dominant polycystic kidney disease","volume":"97","author":"Devuyst","year":"2020","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.akdh.2025.12.003_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-24104-w","article-title":"Atypical polycystic kidney disease as defined by imaging","volume":"13","author":"Iliuta","year":"2023","journal-title":"Sci Rep"},{"issue":"5","key":"10.1053\/j.akdh.2025.12.003_bib16","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1053\/j.akdh.2023.04.004","article-title":"Genetic spectrum of polycystic kidney and liver diseases and the resulting phenotypes","volume":"30","author":"Yang","year":"2023","journal-title":"Adv Kidney Dis Health"},{"issue":"1","key":"10.1053\/j.akdh.2025.12.003_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/s41525-023-00362-z","article-title":"Atypical splicing variants in PKD1 explain most undiagnosed typical familial ADPKD","volume":"8","author":"Hort","year":"2023","journal-title":"NPJ Genom Med"},{"issue":"1","key":"10.1053\/j.akdh.2025.12.003_bib18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1681\/ASN.2008050507","article-title":"Unified criteria for ultrasonographic diagnosis of autosomal dominant polycystic kidney disease","volume":"20","author":"Pei","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.akdh.2025.12.003_bib19","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials","volume":"26","author":"Irazabal","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.akdh.2025.12.003_bib20","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1681\/ASN.2015010016","article-title":"The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease","volume":"27","author":"Cornec-Le Gall","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.akdh.2025.12.003_bib21","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1681\/ASN.2015060648","article-title":"Refining genotype-phenotype correlation in autosomal dominant polycystic kidney disease","volume":"27","author":"Hwang","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.akdh.2025.12.003_bib22","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.kint.2018.12.023","article-title":"Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease","volume":"95","author":"Yu","year":"2019","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.akdh.2025.12.003_bib23","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2215\/CJN.0000000000000427","article-title":"Validation of the Mayo imaging classification system for predicting kidney outcomes in ADPKD","volume":"19","author":"Bais","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.akdh.2025.12.003_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-61303-9","article-title":"Implications of early diagnosis of autosomal dominant polycystic kidney disease: a post hoc analysis of the TEMPO 3:4 trial","volume":"10","author":"Janssens","year":"2020","journal-title":"Sci Rep"},{"issue":"20","key":"10.1053\/j.akdh.2025.12.003_bib25","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1053\/j.akdh.2025.12.003_bib26","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1053\/j.ajkd.2017.10.023","article-title":"Patterns of kidney function decline in autosomal dominant polycystic kidney disease: a post hoc analysis from the HALT-PKD trials","volume":"71","author":"Brosnahan","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"15","key":"10.1053\/j.akdh.2025.12.003_bib27","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.138724","article-title":"The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD","volume":"5","author":"Lavu","year":"2020","journal-title":"JCI Insight"},{"issue":"8","key":"10.1053\/j.akdh.2025.12.003_bib28","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1159\/000518255","article-title":"Predicting future renal function decline in patients with autosomal dominant polycystic kidney disease using mayo clinic classification","volume":"52","author":"Borrego Utiel","year":"2021","journal-title":"Am J Nephrol"},{"issue":"6","key":"10.1053\/j.akdh.2025.12.003_bib29","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1681\/ASN.2012070650","article-title":"Type of PKD1 mutation influences renal outcome in ADPKD","volume":"24","author":"Cornec-Le Gall","year":"2013","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.akdh.2025.12.003_bib30","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1681\/ASN.2015050583","article-title":"Predicted mutation strength of nontruncating PKD1 mutations AIDS genotype-phenotype correlations in autosomal dominant polycystic kidney disease","volume":"27","author":"Heyer","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.akdh.2025.12.003_bib31","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1053\/j.ajkd.2017.01.046","article-title":"PKD2-Related autosomal dominant polycystic kidney disease: prevalence, clinical presentation, mutation spectrum, and prognosis","volume":"70","author":"Cornec-Le Gall","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"10.1053\/j.akdh.2025.12.003_bib32","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1681\/ASN.2006080835","article-title":"Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease","volume":"17","author":"Harris","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.akdh.2025.12.003_bib33","doi-asserted-by":"crossref","first-page":"715","DOI":"10.34067\/KID.0000000000000433","article-title":"Clinical characteristics and kidney outcomes in Chinese patients with autosomal dominant polycystic kidney disease","volume":"5","author":"Fung","year":"2024","journal-title":"Kidney360"},{"issue":"24","key":"10.1053\/j.akdh.2025.12.003_bib34","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1001\/jama.2022.22847","article-title":"Exome sequencing of a clinical population for autosomal dominant polycystic kidney disease","volume":"328","author":"Chang","year":"2022","journal-title":"JAMA"},{"issue":"11","key":"10.1053\/j.akdh.2025.12.003_bib35","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1681\/ASN.2019030298","article-title":"ALg9 mutation carriers develop kidney and liver cysts","volume":"30","author":"Besse","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.akdh.2025.12.003_bib36","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.ajhg.2022.06.013","article-title":"Monoallelic pathogenic ALG5 variants cause atypical polycystic kidney disease and interstitial fibrosis","volume":"109","author":"Lemoine","year":"2022","journal-title":"Am J Hum Genet"},{"issue":"1","key":"10.1053\/j.akdh.2025.12.003_bib37","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ajhg.2021.11.016","article-title":"Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney-spectrum phenotype","volume":"109","author":"Senum","year":"2022","journal-title":"Am J Hum Genet"},{"issue":"12","key":"10.1053\/j.akdh.2025.12.003_bib38","doi-asserted-by":"crossref","DOI":"10.1002\/ajmg.a.63841","article-title":"Heterozygous loss of function variants in IFT140 are associated with polycystic kidney disease","volume":"194","author":"Clark","year":"2024","journal-title":"Am J Med Genet A"},{"issue":"2","key":"10.1053\/j.akdh.2025.12.003_bib39","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfae026","article-title":"Monoallelic pathogenic IFT140 variants are a common cause of autosomal dominant polycystic kidney disease-spectrum phenotype","volume":"17","author":"Dordoni","year":"2024","journal-title":"Clin Kidney J"},{"issue":"10","key":"10.1053\/j.akdh.2025.12.003_bib40","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.2215\/CJN.02830317","article-title":"A patient with a novel gene mutation leading to autosomal dominant polycystic kidney disease","volume":"12","author":"Reddy","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.akdh.2025.12.003_bib41","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s40620-021-01131-w","article-title":"Expanding the variability of the ADPKD-GANAB clinical phenotype in a family of Italian ancestry","volume":"35","author":"Delbarba","year":"2022","journal-title":"J Nephrol"},{"issue":"5","key":"10.1053\/j.akdh.2025.12.003_bib42","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.ajhg.2018.03.013","article-title":"Monoallelic mutations to DNAJB11 cause atypical autosomal-dominant polycystic kidney disease","volume":"102","author":"Cornec-Le Gall","year":"2018","journal-title":"Am J Hum Genet"},{"issue":"2","key":"10.1053\/j.akdh.2025.12.003_bib43","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.kint.2020.02.022","article-title":"Clinical spectrum, prognosis and estimated prevalence of DNAJB11-kidney disease","volume":"98","author":"Huynh","year":"2020","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.akdh.2025.12.003_bib44","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/ckj\/sfac032","article-title":"More dissimilarities than affinities between DNAJB11-PKD and ADPKD","volume":"15","author":"Pisani","year":"2022","journal-title":"Clin Kidney J"},{"issue":"2","key":"10.1053\/j.akdh.2025.12.003_bib45","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1053\/j.ajkd.2017.09.008","article-title":"ADPKD progression in patients with no apparent family history and no mutation detected by sanger sequencing","volume":"71","author":"Braun","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"10.1053\/j.akdh.2025.12.003_bib46","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1681\/ASN.2010101080","article-title":"Mutations in multiple PKD genes may explain early and severe polycystic kidney disease","volume":"22","author":"Bergmann","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.akdh.2025.12.003_bib47","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/ki.2008.686","article-title":"Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease","volume":"75","author":"Rossetti","year":"2009","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.akdh.2025.12.003_bib48","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1681\/ASN.2014101051","article-title":"Comprehensive PKD1 and PKD2 mutation analysis in prenatal autosomal dominant polycystic kidney disease","volume":"27","author":"Audr\u00e9zet","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.akdh.2025.12.003_bib49","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41436-020-01026-4","article-title":"Biallelic inheritance of hypomorphic PKD1 variants is highly prevalent in very early onset polycystic kidney disease","volume":"23","author":"Durkie","year":"2021","journal-title":"Genet Med"},{"issue":"3","key":"10.1053\/j.akdh.2025.12.003_bib50","doi-asserted-by":"crossref","first-page":"387","DOI":"10.34067\/KID.0000000000000064","article-title":"Hypomorphic PKD1 alleles impact disease variability in autosomal dominant polycystic kidney disease","volume":"4","author":"Gulati","year":"2023","journal-title":"Kidney360"},{"issue":"7","key":"10.1053\/j.akdh.2025.12.003_bib51","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1681\/ASN.2009101070","article-title":"Incompletely penetrant PKD1 alleles mimic the renal manifestations of ARPKD","volume":"21","author":"Vujic","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.akdh.2025.12.003_bib52","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.ekir.2021.12.027","article-title":"Lessons from the clinic: ADPKD genetic test unraveling severe phenotype, intrafamilial variability, and new, rare causing genotype","volume":"7","author":"Izzi","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"12","key":"10.1053\/j.akdh.2025.12.003_bib53","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1681\/ASN.0000000000000249","article-title":"The clinical utility of genetic testing in the diagnosis and management of adults with chronic kidney disease","volume":"34","author":"Dahl","year":"2023","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.akdh.2025.12.003_bib54","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2215\/CJN.0000000000000564","article-title":"Utility of genetic testing in adults with CKD","volume":"20","author":"Schott","year":"2025","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"10.1053\/j.akdh.2025.12.003_bib55","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.34067\/KID.0000000825","article-title":"The art and science of genetic counseling in nephrology","volume":"6","author":"Bogyo","year":"2025","journal-title":"Kidney360"},{"issue":"3","key":"10.1053\/j.akdh.2025.12.003_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ckj\/sfae043","article-title":"Exploring the impact and utility of genomic sequencing in established CKD","volume":"17","author":"Jefferis","year":"2024","journal-title":"Clin Kidney J"},{"issue":"6","key":"10.1053\/j.akdh.2025.12.003_bib57","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1053\/j.ajkd.2018.01.048","article-title":"Preimplantation genetic diagnosis counseling in autosomal dominant polycystic kidney disease","volume":"72","author":"Murphy","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"10.1053\/j.akdh.2025.12.003_bib58","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.ekir.2019.04.018","article-title":"Intrafamilial variability of ADPKD","volume":"4","author":"Lanktree","year":"2019","journal-title":"Kidney Int Rep"},{"issue":"4","key":"10.1053\/j.akdh.2025.12.003_bib59","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/ki.2013.450","article-title":"Whole-exome resequencing distinguishes cystic kidney diseases from phenocopies in renal ciliopathies","volume":"85","author":"Gee","year":"2014","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.akdh.2025.12.003_bib60","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/mgg3.82","article-title":"Diagnosis of autosomal dominant polycystic kidney disease using efficient pkd1 and pkd2 targeted next-generation sequencing","volume":"2","author":"Trujillano","year":"2014","journal-title":"Mol Genet Genomic Med"},{"issue":"2","key":"10.1053\/j.akdh.2025.12.003_bib61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116680","article-title":"An efficient and comprehensive strategy for genetic diagnostics of polycystic kidney disease","volume":"10","author":"Eisenberger","year":"2015","journal-title":"PLoS One"},{"issue":"11","key":"10.1053\/j.akdh.2025.12.003_bib62","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1038\/ejhg.2016.48","article-title":"Whole-genome sequencing overcomes pseudogene homology to diagnose autosomal dominant polycystic kidney disease","volume":"24","author":"Mallawaarachchi","year":"2016","journal-title":"Eur J Hum Genet"},{"issue":"5","key":"10.1053\/j.akdh.2025.12.003_bib63","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/s41431-020-00796-4","article-title":"Genomic diagnostics in polycystic kidney disease: an assessment of real-world use of whole-genome sequencing","volume":"29","author":"Mallawaarachchi","year":"2021","journal-title":"Eur J Hum Genet"},{"issue":"5","key":"10.1053\/j.akdh.2025.12.003_bib64","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of medical genetics and genomics and the association for molecular pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"issue":"2","key":"10.1053\/j.akdh.2025.12.003_bib65","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1053\/j.ajkd.2020.12.020","article-title":"Assessing risk of rapid progression in autosomal dominant polycystic kidney disease and special considerations for disease-modifying therapy","volume":"78","author":"Chebib","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"20","key":"10.1053\/j.akdh.2025.12.003_bib66","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa054341","article-title":"Volume progression in polycystic kidney disease","volume":"354","author":"Grantham","year":"2006","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.akdh.2025.12.003_bib67","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.kint.2017.09.027","article-title":"Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in autosomal dominant polycystic kidney disease","volume":"93","author":"Yu","year":"2018","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.akdh.2025.12.003_bib68","doi-asserted-by":"crossref","DOI":"10.1186\/s12882-017-0654-y","article-title":"Temporal and geographical external validation study and extension of the Mayo clinic prediction model to predict eGFR in the younger population of Swiss ADPKD patients","volume":"18","author":"Girardat-Rotar","year":"2017","journal-title":"BMC Nephrol"},{"issue":"10174","key":"10.1053\/j.akdh.2025.12.003_bib69","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(18)32782-X","article-title":"Autosomal dominant polycystic kidney disease","volume":"393","author":"Cornec-Le Gall","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1053\/j.akdh.2025.12.003_bib70","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2214\/AJR.15.15875","article-title":"Semiautomated segmentation of polycystic kidneys in T2-Weighted MR images","volume":"207","author":"Kline","year":"2016","journal-title":"AJR Am J Roentgenol"},{"issue":"8","key":"10.1053\/j.akdh.2025.12.003_bib71","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1681\/ASN.2018090902","article-title":"Automatic measurement of kidney and liver volumes from MR images of patients affected by autosomal dominant polycystic kidney disease","volume":"30","author":"van Gastel","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.akdh.2025.12.003_bib72","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-47206-4","article-title":"Prognostic performance of kidney volume measurement for polycystic kidney disease: a comparative study of ellipsoid vs. manual segmentation","volume":"9","author":"Shi","year":"2019","journal-title":"Sci Rep"},{"issue":"1","key":"10.1053\/j.akdh.2025.12.003_bib73","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1681\/ASN.2013040398","article-title":"Strategies targeting cAMP signaling in the treatment of polycystic kidney disease","volume":"25","author":"Torres","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"25","key":"10.1053\/j.akdh.2025.12.003_bib74","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1053\/j.akdh.2025.12.003_bib75","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.ekir.2017.07.004","article-title":"Tolerability of Aquaretic-Related symptoms following tolvaptan for autosomal dominant polycystic kidney disease: results from TEMPO 3:4","volume":"2","author":"Devuyst","year":"2017","journal-title":"Kidney Int Rep"},{"issue":"3","key":"10.1053\/j.akdh.2025.12.003_bib76","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.kint.2021.06.013","article-title":"Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD)","volume":"100","author":"Perrone","year":"2021","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.akdh.2025.12.003_bib77","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/j.ajkd.2021.06.026","article-title":"Metformin therapy in autosomal dominant polycystic kidney disease: a feasibility study","volume":"79","author":"Brosnahan","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.akdh.2025.12.003_bib78","article-title":"Metformin for preventing the progression of chronic kidney disease","volume":"6","author":"El-Damanawi","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1053\/j.akdh.2025.12.003_bib80","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.ekir.2025.01.023","article-title":"Open-label, randomized, controlled, crossover trial on the effect of dapagliflozin in patients with ADPKD receiving tolvaptan","volume":"10","author":"Uchiyama","year":"2025","journal-title":"Kidney Int Rep"},{"issue":"12","key":"10.1053\/j.akdh.2025.12.003_bib81","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1093\/ndt\/gfaf061","article-title":"SGLT2 inhibition for patients with ADPKD \u2013 closing the evidence gap","volume":"40","author":"M\u00fcller","year":"2025","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1053\/j.akdh.2025.12.003_bib82","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1053\/j.akdh.2023.01.003","article-title":"Autosomal dominant polycystic kidney disease therapies on the horizon","volume":"30","author":"Zhou","year":"2023","journal-title":"Adv Kidney Dis Health"},{"issue":"1","key":"10.1053\/j.akdh.2025.12.003_bib83","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14395","article-title":"microRNA-17 family promotes polycystic kidney disease progression through modulation of mitochondrial metabolism","volume":"8","author":"Hajarnis","year":"2017","journal-title":"Nat Commun"},{"issue":"1","key":"10.1053\/j.akdh.2025.12.003_bib84","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-11918-y","article-title":"Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease","volume":"10","author":"Lee","year":"2019","journal-title":"Nat Commun"}],"container-title":["Advances in Kidney Disease and Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949813925001417?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949813925001417?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T08:09:10Z","timestamp":1793952550000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949813925001417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":83,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2949813925001417"],"URL":"https:\/\/doi.org\/10.1053\/j.akdh.2025.12.003","relation":{},"ISSN":["2949-8139"],"issn-type":[{"value":"2949-8139","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autosomal Dominant Polycystic Kidney Disease: Genetic Insights, Phenotypic Spectrum, and Advances in Prognosis and Treatment","name":"articletitle","label":"Article Title"},{"value":"Advances in Kidney Disease and Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.akdh.2025.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the National Kidney Foundation, Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}